News

The FDA approved Hernexeos (zongertinib tablets, Boehringer Engelheim) for the treatment of adults with unresectable or metastatic NSCLC, Boehringer Ingelheim announced in a press release. It is the ...
A study led by Roswell Park Comprehensive Cancer Center helps explain why a rare and hyper-aggressive subtype of kidney cancer is susceptible to immunotherapy—information that helped researchers ...
Neuroblastoma can be a particularly insidious cancer. In about half of all cases, tumors regress, even without therapy. In ...
Compugen advances COM701 in ovarian cancer with strong partners, key catalysts ahead, and funding into 2027. Find out why ...
Cancer research is an ever-evolving field, driven by the pressing need to understand and combat a disease that remains a leading cause of morbidity and ...
LMO2 is an intrinsically disordered transcription factor activated in T cell leukaemia that is difficult to target. It forms part of a multiprotein complex that has bipartite DNA binding through ...
HOXB13, a B-class homeobox transcription factor, sits at the hub of developmental gene networks yet has emerged as a double-edged sword in human cancer.
HOXB13, a B-class homeobox transcription factor, sits at the hub of developmental gene networks yet has emerged as a ...
Research and Development (R&D) Expenses: R&D expenses were $12.2 million for the second quarter of 2025, compared to $14.7 million for the same period in 2024. General and Administrative (G&A) ...
A new study is shedding light on an important connection between human evolution and cancer. It reveals that some of the very genes that helped make our brains smarter are also being misused by cancer ...
HOXB13, a B-class homeobox transcription factor, sits at the hub of developmental gene networks yet has emerged as a ...